Our study used targeted proteomics of CSF and plasma samples from 354 participants to identify Hub and Critical proteins that are significantly associated with clinical AD related phenotypes and CSF AD biomarker (Aβ42, Tau, pTau) as markers of AD pathology. This evidence concerns the gene MAPT and Alzheimer disease.